Physician profile
Rano T Mathew
NPI 1972694297
$14,737.86
in general payments reported to CMS, 2019-2025
38 companies · $2,058 in 2025
The $2,058 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,628 · 2020: $766 · 2021: $1,378 · 2022: $1,522 · 2023: $3,006 · 2024: $4,380 · 2025: $2,058.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,432 · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,432.20 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,632.30 | 2019-2025 | Spravato, Invega Sustenna |
| Neurocrine Biosciences, INC. | $1,288.20 | 2019-2025 | Ingrezza |
| Vanda Pharmaceuticals INC. | $1,282.47 | 2022-2025 | Fanapt, Hetlioz |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $1,281.46 | 2020-2025 | Caplyta |
| Otsuka America Pharmaceutical, INC. | $969.10 | 2019-2025 | Rexulti, Abilify Maintena |
| Abbvie INC. | $922.33 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $874.20 | 2019-2024 | Austedo Xr, Austedo, Uzedy |
| Axsome Therapeutics, INC. | $710.92 | 2023-2025 | Auvelity |
| Neos Therapeutics, LP | $514.93 | 2019-2024 | Adzenys Xr-Odt |
| Bausch Health US, LLC | $485.07 | 2019-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $430.34 | 2022-2025 | Azstarys |
| Eisai INC. | $407.28 | 2020-2022 | |
| Alkermes, INC. | $385.00 | 2022-2025 | Lybalvi, Aristada, Vivitrol |
| Lundbeck LLC | $378.58 | 2019-2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $356.58 | 2022-2023 | Quviviq |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rano Mathew listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.